Metelimumab
Metelimumab
Metelimumab (pronunciation: meh-tel-ee-moo-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a type of biopharmaceutical that is produced through recombinant DNA technology.
Etymology
The name "Metelimumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Meteli-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Metelimumab works by binding to specific proteins on the surface of certain immune cells. This binding can block the activity of these proteins, which can help to reduce the immune response that is causing the autoimmune disease.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Recombinant DNA: DNA that has been formed artificially by combining constituents from different organisms.
See Also
External links
- Medical encyclopedia article on Metelimumab
- Wikipedia's article - Metelimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski